Baldetorp B, Bendahl P O, Fernö M, Alanen K, Delle U, Falkmer U, Hansson-Aggesjö B, Höckenström T, Lindgren A, Mossberg L
Department of Oncology, University Hospital, Lund, Sweden.
Cytometry. 1995 Jun 15;22(2):115-27. doi: 10.1002/cyto.990220207.
Flow cytometric (FCM) DNA analysis yields information on ploidy status and the S-phase fraction (SPF), variables of prognostic importance in breast cancer. The clinical value of the SPF is currently being evaluated in prospective randomized trials. The widespread use of FCM DNA analysis emphasizes the importance of reproducibility (both intra- and interlaboratory). In this study, 67 nuclear suspensions of breast cancer samples were analyzed by 12 laboratories routinely performing FCM DNA analysis in breast cancer. No general guidelines were imposed; each laboratory used its own standard protocols. For DNA ploidy status (diploid vs. non-diploid), agreement was complete for 79% (53/67) of the samples, compared with 64% (43/67) of samples when tetraploidy was considered [i.e., euploid (diploid+tetraploid) vs. aneuploid (the remaining non-diploid)]. For the SPF, pairwise comparison of the results of all 12 laboratories yielded a mean Spearman's rank correlation of 0.78 (range: 0.54-0.93). For those 39 samples being categorized in low or high SPF by all laboratories, all agreed in 14 samples (36%). Similar patterns were obtained with kappa measures, agreement being good for ploidy status (diploid vs. non-diploid; overall kappa = 0.87 and 0.74 for euploid vs. aneuploid), but moderate for the SPF [overall kappa = 0.47 (for low SPF vs. high SPF vs. "no SPF reported")]. Discrepancies were chiefly attributable to differences in the categorization of the S-phase values, rather than in FCM procedures, other critical differences being in the detection and interpretation of near-diploid and small non-diploid cell populations, the definition of tetraploidy, and the choice and execution of the method used for S-phase estimation. Based on the observations of this study, detailed guidelines for FCM analysis and interpretation of data are proposed in the Appendix. Some issues remain, however, e.g., to standardize a method for S-phase calculation and tetraploid definition.
流式细胞术(FCM)DNA分析可提供有关倍体状态和S期分数(SPF)的信息,这些变量在乳腺癌中具有重要的预后意义。目前正在前瞻性随机试验中评估SPF的临床价值。FCM DNA分析的广泛应用强调了可重复性(包括实验室内和实验室间)的重要性。在本研究中,12个常规进行乳腺癌FCM DNA分析的实验室对67份乳腺癌样本的核悬液进行了分析。未施加通用指南;每个实验室都使用自己的标准方案。对于DNA倍体状态(二倍体与非二倍体),79%(53/67)的样本完全一致,而考虑四倍体时(即整倍体(二倍体+四倍体)与非整倍体(其余非二倍体)),样本一致率为64%(43/67)。对于SPF,所有12个实验室结果的成对比较得出平均Spearman等级相关性为0.78(范围:0.54 - 0.93)。对于所有实验室都归类为低或高SPF的39个样本,14个样本(36%)完全一致。kappa测量也得到了类似的结果,倍体状态(二倍体与非二倍体;整倍体与非整倍体的总体kappa分别为0.87和0.74)一致性良好,但SPF的一致性中等[总体kappa = 0.47(低SPF与高SPF与“未报告SPF”)]。差异主要归因于S期值分类的不同,而非FCM程序,其他关键差异在于近二倍体和小非二倍体细胞群体的检测和解释、四倍体的定义以及用于S期估计的方法的选择和执行。基于本研究的观察结果,附录中提出了FCM分析和数据解释的详细指南。然而,仍有一些问题,例如,标准化S期计算方法和四倍体定义。